Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy Controls

The objective of this study was to compare participants at-risk for trauma-related neurodegeneration to a healthy control group on outcomes associated with Alzheimer’s disease (AD), such as subjective symptoms, neurocognitive performance, plasma biomarkers, volumetrics, amyloid-beta (Aβ) positron em...

Full description

Saved in:
Bibliographic Details
Main Authors: Shawn R. Eagle, Ava Puccio, Sarah Svirsky, James Mountz, Charles Laymon, Allison Borasso, Luke Henry, David O. Okonkwo
Format: Article
Language:English
Published: Mary Ann Liebert 2025-01-01
Series:Neurotrauma Reports
Subjects:
Online Access:https://www.liebertpub.com/doi/10.1089/neur.2025.0052
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839642104490360832
author Shawn R. Eagle
Ava Puccio
Sarah Svirsky
James Mountz
Charles Laymon
Allison Borasso
Luke Henry
David O. Okonkwo
author_facet Shawn R. Eagle
Ava Puccio
Sarah Svirsky
James Mountz
Charles Laymon
Allison Borasso
Luke Henry
David O. Okonkwo
author_sort Shawn R. Eagle
collection DOAJ
description The objective of this study was to compare participants at-risk for trauma-related neurodegeneration to a healthy control group on outcomes associated with Alzheimer’s disease (AD), such as subjective symptoms, neurocognitive performance, plasma biomarkers, volumetrics, amyloid-beta (Aβ) positron emission tomography (PET), and tau PET. Participants completed a comprehensive assessment protocol for neurodegenerative disease, including magnetic resonance imaging (MRI), PET scans for tau and Aβ, blood draw, subjective symptom reports related to neurodegenerative disease, and objective neurocognitive assessment. Surveys included the Neurobehavioral Symptom Inventory (NSI), Insomnia Severity Index (ISI), Epworth Sleepiness Severity (ESS), PTSD Checklist for DSM-5 (PCL-5), Brief Symptom Inventory-18 (BSI-18), Satisfaction with Life Scale (SWLS), Barratt Impulsivity Scale (BIS), and Buss Perry Aggression Questionnaire (BPAQ). PET scans were read by a neuroradiologist and rated positive or negative based upon established cutoffs. General linear models compared participants with TBI history with controls on outcomes. Age, years of education, military status, biological sex, race/ethnicity, and total self-reported TBIs were included as covariates in all models with Bonferroni corrections. Forward stepwise linear regression models were built to associate neuroimaging outcomes with symptom domains; inclusion in the linear regression required a p value <0.1. The average age for both groups was ∼40 years. The TBI group reported an average of five TBIs; the control group reported an average of one TBI. Across seven regions of interest, only one TBI participant met established PET cutoffs for neuropathology in one cortical region. After controlling for age, sex, race/ethnicity, years of education, military status, and TBI history, there were no statistically significant differences between groups in any neurocognitive outcome (p = 0.06–0.95), Aβ or tau PET (p = 0.05–0.70), MRI volumetrics (p = 0.06–0.98), or plasma biomarkers (p = 0.06–0.85). The TBI group had higher NSI, PCL-5, BSI-18, BPAQ, ESS, and ISI scores compared with the controls (p < 0.001–0.042). Within the TBI group, amygdala normative percentile and/or amygdala asymmetry index were included in the final models for NSI, SWLS, PCL5, BIS, BPAQ, and ISI. Only two models included a statistically significant PET outcome in the final model. In this sample with a mean age of 40 and a history of 5+ TBIs, core diagnostic biomarkers for AD were not different from controls despite significantly higher symptom burden. Volumetrics in critical brain regions were associated with several symptom domains in the TBI group, indicating that cortical volumetrics (especially in the amygdala) may be a more viable early biomarker of chronic symptom burden in this population than PET scans.
format Article
id doaj-art-b46bd0c54b5646c9b43f36c1d1857cfc
institution Matheson Library
issn 2689-288X
language English
publishDate 2025-01-01
publisher Mary Ann Liebert
record_format Article
series Neurotrauma Reports
spelling doaj-art-b46bd0c54b5646c9b43f36c1d1857cfc2025-07-02T17:05:53ZengMary Ann LiebertNeurotrauma Reports2689-288X2025-01-016156056810.1089/neur.2025.0052Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy ControlsShawn R. Eagle0Ava Puccio1Sarah Svirsky2James Mountz3Charles Laymon4Allison Borasso5Luke Henry6David O. Okonkwo7Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.The objective of this study was to compare participants at-risk for trauma-related neurodegeneration to a healthy control group on outcomes associated with Alzheimer’s disease (AD), such as subjective symptoms, neurocognitive performance, plasma biomarkers, volumetrics, amyloid-beta (Aβ) positron emission tomography (PET), and tau PET. Participants completed a comprehensive assessment protocol for neurodegenerative disease, including magnetic resonance imaging (MRI), PET scans for tau and Aβ, blood draw, subjective symptom reports related to neurodegenerative disease, and objective neurocognitive assessment. Surveys included the Neurobehavioral Symptom Inventory (NSI), Insomnia Severity Index (ISI), Epworth Sleepiness Severity (ESS), PTSD Checklist for DSM-5 (PCL-5), Brief Symptom Inventory-18 (BSI-18), Satisfaction with Life Scale (SWLS), Barratt Impulsivity Scale (BIS), and Buss Perry Aggression Questionnaire (BPAQ). PET scans were read by a neuroradiologist and rated positive or negative based upon established cutoffs. General linear models compared participants with TBI history with controls on outcomes. Age, years of education, military status, biological sex, race/ethnicity, and total self-reported TBIs were included as covariates in all models with Bonferroni corrections. Forward stepwise linear regression models were built to associate neuroimaging outcomes with symptom domains; inclusion in the linear regression required a p value <0.1. The average age for both groups was ∼40 years. The TBI group reported an average of five TBIs; the control group reported an average of one TBI. Across seven regions of interest, only one TBI participant met established PET cutoffs for neuropathology in one cortical region. After controlling for age, sex, race/ethnicity, years of education, military status, and TBI history, there were no statistically significant differences between groups in any neurocognitive outcome (p = 0.06–0.95), Aβ or tau PET (p = 0.05–0.70), MRI volumetrics (p = 0.06–0.98), or plasma biomarkers (p = 0.06–0.85). The TBI group had higher NSI, PCL-5, BSI-18, BPAQ, ESS, and ISI scores compared with the controls (p < 0.001–0.042). Within the TBI group, amygdala normative percentile and/or amygdala asymmetry index were included in the final models for NSI, SWLS, PCL5, BIS, BPAQ, and ISI. Only two models included a statistically significant PET outcome in the final model. In this sample with a mean age of 40 and a history of 5+ TBIs, core diagnostic biomarkers for AD were not different from controls despite significantly higher symptom burden. Volumetrics in critical brain regions were associated with several symptom domains in the TBI group, indicating that cortical volumetrics (especially in the amygdala) may be a more viable early biomarker of chronic symptom burden in this population than PET scans.https://www.liebertpub.com/doi/10.1089/neur.2025.0052morphometricsneurodegenerationplasma biomarkerspositron emission tomographysymptomsTBI
spellingShingle Shawn R. Eagle
Ava Puccio
Sarah Svirsky
James Mountz
Charles Laymon
Allison Borasso
Luke Henry
David O. Okonkwo
Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy Controls
Neurotrauma Reports
morphometrics
neurodegeneration
plasma biomarkers
positron emission tomography
symptoms
TBI
title Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy Controls
title_full Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy Controls
title_fullStr Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy Controls
title_full_unstemmed Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy Controls
title_short Identifying a Biological Signature of Trauma-Related Neurodegeneration Following Repeated Traumatic Brain Injuries Compared with Healthy Controls
title_sort identifying a biological signature of trauma related neurodegeneration following repeated traumatic brain injuries compared with healthy controls
topic morphometrics
neurodegeneration
plasma biomarkers
positron emission tomography
symptoms
TBI
url https://www.liebertpub.com/doi/10.1089/neur.2025.0052
work_keys_str_mv AT shawnreagle identifyingabiologicalsignatureoftraumarelatedneurodegenerationfollowingrepeatedtraumaticbraininjuriescomparedwithhealthycontrols
AT avapuccio identifyingabiologicalsignatureoftraumarelatedneurodegenerationfollowingrepeatedtraumaticbraininjuriescomparedwithhealthycontrols
AT sarahsvirsky identifyingabiologicalsignatureoftraumarelatedneurodegenerationfollowingrepeatedtraumaticbraininjuriescomparedwithhealthycontrols
AT jamesmountz identifyingabiologicalsignatureoftraumarelatedneurodegenerationfollowingrepeatedtraumaticbraininjuriescomparedwithhealthycontrols
AT charleslaymon identifyingabiologicalsignatureoftraumarelatedneurodegenerationfollowingrepeatedtraumaticbraininjuriescomparedwithhealthycontrols
AT allisonborasso identifyingabiologicalsignatureoftraumarelatedneurodegenerationfollowingrepeatedtraumaticbraininjuriescomparedwithhealthycontrols
AT lukehenry identifyingabiologicalsignatureoftraumarelatedneurodegenerationfollowingrepeatedtraumaticbraininjuriescomparedwithhealthycontrols
AT davidookonkwo identifyingabiologicalsignatureoftraumarelatedneurodegenerationfollowingrepeatedtraumaticbraininjuriescomparedwithhealthycontrols